Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytotoxin-associated gene A (CagA) is a major virulence factor and the first identified bacterial oncoprotein, produced by highly pathogenic strains of Helicobacter pylori. Following bacterial attachment to gastric epithelial cells, CagA is translocated into the host cytoplasm via a type IV secretion system (T4SS). Once intracellular, it undergoes tyrosine phosphorylation by host Src and Abl family kinases at specific EPIYA motifs, allowing it to act as a non-physiological scaffold that hijacks various signaling pathways. Primarily, it interacts with the protein tyrosine phosphatase SHP2, leading to sustained MAPK/ERK activation, which drives abnormal cell proliferation, motility, and the characteristic 'hummingbird' morphological phenotype. CagA also interacts with polarity-regulating kinases and tumor suppressors like ASPP2 to promote epithelial-to-mesenchymal transition and genomic instability. Its presence is strongly correlated with an increased risk of gastric adenocarcinoma, peptic ulcers, and MALT lymphoma. Due to its central role in H. pylori-induced malignancy and the rising challenge of antibiotic resistance, CagA is a high-priority therapeutic target for the development of virulence-attenuating drugs and prophylactic vaccines.
Inhibition of CagA delivery by targeting the bacterial type IV secretion system (T4SS), prevention of intracellular tyrosine phosphorylation by host-cell kinases, disruption of pathogenic protein-protein interactions with host effectors such as SHP2 or ASPP2, and vaccine-induced neutralizing antibody production.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytotoxin-associated gene A protein (CagA) (CagA).